GlassScriptPhysician profile
Richard Bowen
NPI 1497347975
$8,676.26
in general payments reported to CMS, 2019-2025
21 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.79 · 2023: $2,483 · 2024: $3,538 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,178 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,177.56 |
| Education | $482.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,897.92 | 2023-2025 | |
| Janssen Biotech, INC. | $1,110.54 | 2023-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $1,034.95 | 2023-2025 | Ycanth |
| Amgen INC. | $680.14 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $633.54 | 2023-2025 | Opzelura, Iclusig |
| Genzyme Corporation | $597.70 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $437.70 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $383.59 | 2024-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $371.54 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $288.26 | 2023-2024 | Vtama |
| Ucb, INC. | $275.40 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $261.07 | 2023-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $141.12 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.80 | 2023 | Spevigo |
| Lilly USA, LLC | $114.69 | 2022-2025 | Ebglyss, Taltz, Olumiant |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $109.92 | 2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $88.91 | 2023-2025 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $72.80 | 2024-2025 | Nemluvio |
| Smith+Nephew, INC. | $24.61 | 2024 | Grafix Pl |
| Journey Medical Corporation | $21.11 | 2024 | |
| Organon LLC | $5.95 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.